Biotech
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (4 June) published the UK’s first official guidance to support the safe development and use of phage therapies – treatments that use viruses to target and destroy harmful bacteria. The guidance aims to help researchers and companies develop phage-based medicines that meet UK safety, quality [...]
Finnish medtech startup AIATELLA has secured €2 million in funding to accelerate the development and scaling of its AI-powered cardiovascular imaging technology. The funding will help the company conduct clinical trials and develop its ultrasound-based preventative screening, which detects and quantifies carotid artery narrowing in minutes. The round was led by Helsinki-based Nordic Science Investments, with Specialist VC, Harjavalta Ventures, [...]
Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr. Elaine Sullivan as Senior Independent Non-Executive Director, bringing extensive global pharma and business expertise to the company. Elaine will take a leading role at Ochre, supporting the board and the corporate strategy, drawing on knowledge from her positions as [...]
Biotechnology company kyron.bio today announced a €5.5 million funding round. The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneur First, Saras Capital, and numerous reputable angel investors. The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies. Additionally, the funding [...]
AI and RNA sequencing company Biostate AI has announced the successful completion of a $12M Series A funding round, led by Accel. The funds will support the company’s mission to unlock affordable and integrated precision medicine, starting with RNA sequencing (RNAseq) services for US-based molecular research. The company’s immediate focus is revolutionising RNAseq accessibility and [...]
Why silence is not a strategy – It’s a risk By Fern Lazar, Managing Partner, Global Health Practice Leader at FINN Partners When the biotech market is booming, even companies that whisper are heard. Capital flows freely, IPOs are plentiful, and early-stage promises often ride the wave of sector momentum. But in a slump — [...]
The biotechnology industry is undergoing a profound digital transformation, with artificial intelligence (AI), cloud computing, and real-time analytics reshaping drug discovery, personalised medicine, and healthcare delivery. By Kevin Cramer, CEO, Sapio Sciences Despite these advancements, the sector still faces challenges in fully realising the potential of digital maturity compared to other industries. Looking ahead to [...]
A new collaboration will use generative AI for the early discovery stage of novel Central Nervous System (CNS) disease therapies, developing small molecule inhibitors from scratch. The collaboration is between biotech company Insilico Medicine and biopharma company Tenacia Biotechnology. The collaboration will combine Insilico’s Pharma.AI - a generative AI-based drug discovery platform - and its [...]
Creation of a genetic representation for more than 2.5 billion people across the Middle East and South Asia could make a major contribution towards advancing precision medicine. Traditional genetic research has mainly relied on linear reference genomes, which is like having a single, standard version of human DNA that scientists compare everyone's genetic information against. [...]
A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine, exploring how gene editing is transforming the way we approach tissue repair and disease treatment. Regenerative medicine aims to repair or replace damaged tissues and organs, offering hope for patients with [...]
